Novartis AG

NOVN

CH0012005267

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 08:04:59 2026-02-13 am EST			5-day change	1st Jan Change
124.73 ^CHF	+0.75%		+3.82%	+13.63%

05:40am	Novartis Says Vanrafia Late-Stage Data Support Slowing of Kidney Function Decline in IgA Nephropathy Patients	MT
05:17am	European Midday Briefing : AI Nerves Linger Ahead of U.S. Inflation Data	DJ

Novartis Receives US FDA Breakthrough Therapy Designation for Ianalumab to Treat Sjogren's Disease

Published on 01/16/2026 at 12:24 pm EST

MT Newswires

Latest news about Novartis AG

05:40am	Novartis Says Vanrafia Late-Stage Data Support Slowing of Kidney Function Decline in IgA Nephropathy Patients	MT
05:17am	European Midday Briefing : AI Nerves Linger Ahead of U.S. Inflation Data	DJ
04:50am	Novartis Announces Final Results from the Phase III ALIGN Study	CI
03:44am	PRESS DIGEST-Wall Street Journal - February 13	RE
02:19am	Novartis' Vanrafia Slows Kidney Function Decline in Late-stage Study	MT
01:55am	Novartis Says Vanrafia Drug Slows Kidney Function Decline	DJ
01:26am	Novartis Vanrafia® Phase III data support slowing of kidney function decline	RE
01:16am	Novartis Vanrafia(R) Phase III data support slowing of kidney function decline in patients with IgA nephropathy	DJ
Feb. 12	Central Garden & Pet Appoints Kay M. Schwichtenberg as New Director, Effective March 1, 2026	CI
Feb. 12	Oryzon Genomics, S.A. Announces Chief Medical Officer For CNS Programs Changes	CI
Feb. 12	NOVARTIS AG : Deutsche Bank maintains a Buy rating	ZD
Feb. 12	NOVARTIS AG : JP Morgan gives a Buy rating	ZD
Feb. 12	Swiss stocks - Factors to watch on February 12	RE
Feb. 11	Swiss Stocks Close Higher; Schindler Shares Drop	MT
Feb. 11	Niowave and Novartis enter global actinium-225 Supply Agreement to advance next-generation cancer therapies	RE
Feb. 11	Niowave and Novartis Enter Global Actinium-225 Supply Agreement to Advance Next-Generation Cancer Therapies	CI
Feb. 09	Entera Bio Ltd. Announces Board Changes	CI
Feb. 09	NOVARTIS AG : Reduced to Neutral by DZ Bank	ZD
Feb. 09	Lilly bets on next-generation cell therapy with $2.4 billion deal for Orna	RE
Feb. 09	European Stock Markets Buoyed by Wall Street and Japan
Feb. 08	Novartis Starts Research Center Development in US Under $23 Billion Investment Push	MT
Feb. 06	Novartis Canada Receives Positive Draft Recommendation from Canada's Drug Agency for All Eligible Early Breast Cancer Patients At High Risk of Recurrence	CI
Feb. 06	Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery	DJ
Feb. 06	Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery	DJ
Feb. 06	NOVARTIS AG : UBS reiterates its Neutral rating	ZD

Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows: - oncology (30.9%); - immunology (18.9%); - cardiovascular, renal and metabolic diseases (16.4%); - neuroscience (11%). The remaining net sales (22.8%) are from contract manufacturing of pharmaceutical products. At the end of 2025, Novartis AG had over 31 production sites worldwide. Net sales are distributed geographically as follows: Switzerland (2.6%), Europe (28.1%), the United States (42.8%), Asia/Africa/Australasia (19.8%), Canada and Latin America (6.7%).

Employees

75,267

Sector

Pharmaceuticals

Calendar

Mar. 02 - TD Cowen Health Care Conference

More about the company